Experimental Drugs for the Treatment of Hepatitis D

Chronic hepatitis D virus infection is the most severe form of viral hepatitis. Antiviral treatment is urgently needed to prevent patients from developing end stage liver disease or hepatocellular carcinoma. Treatment options were limited to off-label use of pegylated interferon alfa until condition...

Descripción completa

Detalles Bibliográficos
Autores principales: Sandmann, Lisa, Cornberg, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057838/
https://www.ncbi.nlm.nih.gov/pubmed/33889032
http://dx.doi.org/10.2147/JEP.S235550
_version_ 1783680909766033408
author Sandmann, Lisa
Cornberg, Markus
author_facet Sandmann, Lisa
Cornberg, Markus
author_sort Sandmann, Lisa
collection PubMed
description Chronic hepatitis D virus infection is the most severe form of viral hepatitis. Antiviral treatment is urgently needed to prevent patients from developing end stage liver disease or hepatocellular carcinoma. Treatment options were limited to off-label use of pegylated interferon alfa until conditional approval of bulevirtide by the EMA (European Medicines Agency) in July 2020. However, several other antiviral compounds are currently investigated and represent promising agents for the treatment of chronic HDV infection.
format Online
Article
Text
id pubmed-8057838
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-80578382021-04-21 Experimental Drugs for the Treatment of Hepatitis D Sandmann, Lisa Cornberg, Markus J Exp Pharmacol Review Chronic hepatitis D virus infection is the most severe form of viral hepatitis. Antiviral treatment is urgently needed to prevent patients from developing end stage liver disease or hepatocellular carcinoma. Treatment options were limited to off-label use of pegylated interferon alfa until conditional approval of bulevirtide by the EMA (European Medicines Agency) in July 2020. However, several other antiviral compounds are currently investigated and represent promising agents for the treatment of chronic HDV infection. Dove 2021-04-16 /pmc/articles/PMC8057838/ /pubmed/33889032 http://dx.doi.org/10.2147/JEP.S235550 Text en © 2021 Sandmann and Cornberg. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Sandmann, Lisa
Cornberg, Markus
Experimental Drugs for the Treatment of Hepatitis D
title Experimental Drugs for the Treatment of Hepatitis D
title_full Experimental Drugs for the Treatment of Hepatitis D
title_fullStr Experimental Drugs for the Treatment of Hepatitis D
title_full_unstemmed Experimental Drugs for the Treatment of Hepatitis D
title_short Experimental Drugs for the Treatment of Hepatitis D
title_sort experimental drugs for the treatment of hepatitis d
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057838/
https://www.ncbi.nlm.nih.gov/pubmed/33889032
http://dx.doi.org/10.2147/JEP.S235550
work_keys_str_mv AT sandmannlisa experimentaldrugsforthetreatmentofhepatitisd
AT cornbergmarkus experimentaldrugsforthetreatmentofhepatitisd

Ejemplares similares